...
| WMDA Standard | Title and link to document | Explanation | Status |
|---|---|---|---|
3.13 4.09 | Unrelated hematopoietic stem cell donors as research subjects Bone Marrow Transplantation (2011), 46: 10-13 | Discuss various implications of research participation of unrelated stem cell donors in research protocols. | Current (2017) |
| 10.13 | Donor and liability of donor registries, donor centres and collection centres-recommendations Bone Marrow Transplantation (2004), 33: 467-470 | The paper outlines the ethical aspects of liability of involved parties and the need for insurance coverage. The article has shortcoming with the respect to legal advices. | Under review (2017), for more details: |
| 5.04.1 | GRID: Moving to Unique Donor Identifier | A public webpage with educational materials to implement GRID in a registry | Current (2018) |
2.11 2.11.1 | WMDA Quality Manual | A template quality manual for organisations that prepare for WMDA Qualification/Accreditation | Current (2017) |
| Related donors | Family donor care management: principles and recommendations Bone Marrow Transplantation (2010) 45: 1269-1273 | This document hopes to encourage increased collaboration between those caring for related and unrelated donors, and build on the extensive work, which has already been undertaken in this field to homogenize care. | Current (2017) |
| 1.07 | Criteria for Evaluation of Transplant Centres | Develop criteria and a form to evaluate TCs in the following situations:
TC does not need to evaluated if the following apply:
| Under development see: https://share.wmda.info/x/IACjE |
...
| WMDA Standard | Title and link to document | Explanation | Status |
|---|---|---|---|
8.05 | WMDA recommendation on the use of biosimilar filgrastims | Current (2018) | |
| 3.03 | Blood (2010) 117: 21-25 | This paper describes the reasons that the WMDA continues to believe that HSC donors should not be paid due to ethical concerns raised by remuneration, potential to damage the public will to act altruistically, the potential for coercion and exploitation of donors, increased risk to patients, harm to local transplantation programs and international stem cell exchange, and the possibility of benefiting some patients while disadvantaging others. | Current (2017) |
| 1.08 | Bone Marrow Transplantation (2018) | This paper describes the general requirements and recommendations for collaboration with the collection and apheresis centers and define critical procedures for the collection of the stem cell product, such as information session, medical assessment, product collection, quality controls, product handover for transportation, and donor follow-up. The specific guidelines are accompanied by detailed checklists and forms that can be found in Supplementary Information and may be used during an initial or follow-up on-site or paper-based audit. For more information you can visit: https://share.wmda.info/x/OAKQEQ | Current (2018) |
| 8.07.1 | Introduction and Importance of a Globally Unique Identity and Labelling Format (ISBT-128) | This position paper encourages the benefit and criticality of a globally unique numbering system, WMDA recognizes the ISBT 128 labelling standard as one that supports full traceability of cellular therapy products from the donor to the patient bedside and the flexibility to protect confidential information as defined by current and future international regulations. | Under revision. Paper is from 2010. |
| 8.08 | The paper describes recommendations for couriers and the transportation of haematopoietic progenitor cells. | Current (2017) | |
| 8.08 | Validation of Product Transportation Containers | Develop WMDA guidelines for validation of transport containers used for the distribution of HSC products | To be developed |
Post-donation
| WMDA Standard | Title and link to document | Explanation | Status |
|---|---|---|---|
9.03, 9.04 | Safety of Living Donation of Hematopoietic Stem Cells Transplantation (2016) 100: 1329-1331 | This paper describes a decade of detailed examination of adverse donor events. | Current (2018) |
| 9.03, 9.04, 5.04.1 | Inadvertent completely HLA-mismatched allogeneic unrelated bone marrow transplant: lessons learned. Bone Marrow Transplantation (2016) 51: 1016-1018 | This paper describes a serious adverse event in which a patient was transplanted with stem cells from an incorrect donor due in large part to the inappropriate use of a supposedly unique donor identifier. | Current (2018) |
| 9.03, 9.04 | Bone Marrow Transplantation (2013) 48: 1506-1509 | This paper described that WMDA has successfully implemented a reporting system for serious adverse events and reactions. | Current (2018) |
...